WILD-TYPE Tp53 UNDERGOES A CELL TYPE-SPECIFIC INACTIVATION BY SIRT1 IN DE NOVO GLIOBLASTOMA

被引：0
|
作者：
Li, Li [1 ]
Vemireddy, Vamsidhara [1 ]
Goodarzi, Mohammad [1 ]
Mashimo, Tomoyuki [1 ]
Billman, Tara [1 ]
Hatanpaa, Kimmo [1 ]
Mickey, Bruce [1 ]
Maher, Elizabeth [1 ]
Bachoo, Robert [1 ]
Piccirillo, Sara [1 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GENE-03
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [1] Dissecting the functional impairment of wild-type Tp53 in human glioblastoma
    Garcia-Montano, Leopoldo A.
    Munoz, Yamhilette Licon
    Martinez, Frank
    Gallegos, Kandee
    Kang, Huining
    Piccirillo, Sara G.
    CANCER RESEARCH, 2023, 83 (07)
  • [2] Wild-type sequence of TP53, intron 7
    Eicheler, W
    Baumann, M
    RADIATION RESEARCH, 2001, 155 (04) : 641 - 641
  • [3] NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells
    Zhang, Yu
    Yu, Hao
    He, Mengyao
    Liu, Wenchao
    Xiao, Shengyou
    Wang, Xiangting
    Huang, Ping
    Huang, Qiang
    NEOPLASMA, 2024, 71 (03) : 255 - 265
  • [4] Poor survival with wild-type TP53 ovarian cancer?
    Wong, Kwong-Kwok
    Izaguirre, Daisy I.
    Kwan, Suet-Yan
    King, Erin R.
    Deavers, Michael T.
    Sood, Anil K.
    Mok, Samuel C.
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2013, 130 (03) : 565 - 569
  • [5] Expression of wild-type and mutated TP53 in breast carcinomas
    Baumbusch, LO
    Myhre, S
    Langerod, A
    Bergamaschi, A
    Johnsen, H
    Geisler, S
    Lonning, PE
    Borresen-Dale, AL
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S53 - S53
  • [6] CRISPR screens are feasible in TP53 wild-type cells
    Brown, Kevin R.
    Mair, Barbara
    Soste, Martin
    Moffat, Jason
    MOLECULAR SYSTEMS BIOLOGY, 2019, 15 (08)
  • [7] Molecular and genetic determinants of dysfunctional wild type TP53 in glioblastoma
    Zhao, Y.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S27 - S28
  • [8] Reply to "CRISPR screens are feasible in TP53 wild-type cells"
    Haapaniemi, Emma
    Botla, Sandeep
    Persson, Jenna
    Schmierer, Bernhard
    Taipale, Jussi
    MOLECULAR SYSTEMS BIOLOGY, 2019, 15 (08)
  • [9] Complete loss of wild-type TP53 in a nontransformed human epithelial cell line is preceded by a phase during which a heterozygous TP53 mutant effectively outgrows the homozygous wild-type cells
    Villadsen, R
    Nielsen, KV
    Bolund, L
    Briand, P
    CANCER GENETICS AND CYTOGENETICS, 2000, 116 (01) : 28 - 34
  • [10] How wild-type TP53 is inactivated in undifferentiated-type gastric carcinomas:: Analyses of intratumoral heterogeneity in deletion and mutation of TP53
    Yoshimura, Akinobu
    Sugihara, Hiroyuki
    Ling, Zhi-Qiang
    Peng, Dun-Fa
    Mukaisho, Ken-ichi
    Fujiyama, Yoshihide
    Hattori, Takanori
    PATHOBIOLOGY, 2006, 73 (01) : 40 - 49
12345